Could a gentler dose of an oral chemo drug help MDS patients avoid transfusions?
Disease control
Completed
This study tested an oral drug called ASTX727 in people with lower-risk myelodysplastic syndromes (MDS), a bone marrow disorder. The goal was to see if a lower dose given over a longer schedule could improve blood cell counts and reduce the need for transfusions. The trial enroll…
Phase: PHASE1, PHASE2 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC